Browsing Tag
Yupelri
3 posts
Zymeworks (ZYME) to buy Theravance (TBPH) for $929m in cash plus ampreloxetine CVR
Zymeworks (ZYME) to acquire Theravance (TBPH) for $17/share plus CVR, $929M equity value. Non-recourse OMERS financing minimises ZYME's cash at risk.
A $260.7m COPD market is opening up. Can Lupin Limited (NSE: LUPIN) turn approval into revenue?
A COPD generic opens a $260.7M U.S. door for Lupin Limited. The bigger test is launch timing, competition, and margin discipline.
Theravance Biopharma (NASDAQ: TBPH) drops rare disease drug after Phase 3 failure triggers strategic review
Theravance Biopharma drops its rare disease drug after a Phase 3 failure. Explore what this means for NASDAQ: TBPH and biotech investors.